Literature DB >> 28283652

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.

Hermela Shimelis1, Romy L S Mesman2, Catharina Von Nicolai3, Asa Ehlen3, Lucia Guidugli4, Charlotte Martin5, Fabienne M G R Calléja2, Huong Meeks6, Emily Hallberg7, Jamie Hinton7, Jenna Lilyquist7, Chunling Hu1, Cora M Aalfs8, Kristiina Aittomäki9, Irene Andrulis10,11, Hoda Anton-Culver12, Volker Arndt13, Matthias W Beckmann14, Javier Benitez15,16, Natalia V Bogdanova17,18, Stig E Bojesen19,20,21, Manjeet K Bolla22, Anne-Lise Borresen-Dale23,24, Hiltrud Brauch25,26,27, Paul Brennan28, Hermann Brenner13,27,29, Annegien Broeks30, Barbara Brouwers31,32, Thomas Brüning33, Barbara Burwinkel34,35, Jenny Chang-Claude36,37, Georgia Chenevix-Trench, Ching-Yu Cheng38, Ji-Yeob Choi39,40, J Margriet Collée41, Angela Cox42, Simon S Cross43, Kamila Czene44, Hatef Darabi44, Joe Dennis22, Thilo Dörk18, Isabel Dos-Santos-Silva45, Alison M Dunning46, Peter A Fasching14,47, Jonine Figueroa48,49, Henrik Flyger50, Montserrat García-Closas49, Graham G Giles51,52, Gord Glendon10, Pascal Guénel53, Christopher A Haiman54, Per Hall44, Ute Hamann55, Mikael Hartman56,57, Frans B Hogervorst30, Antoinette Hollestelle58, John L Hopper52, Hidemi Ito59,60, Anna Jakubowska61, Daehee Kang39,40,62, Veli-Matti Kosma63,64,65, Vessela Kristensen, Kah-Nyin Lai66,67, Diether Lambrechts68,69, Loic Le Marchand70, Jingmei Li44, Annika Lindblom71, Artitaya Lophatananon72, Jan Lubinski61, Eva Machackova73, Arto Mannermaa63,64,65, Sara Margolin74, Frederik Marme34,75, Keitaro Matsuo60,76, Hui Miao56, Kyriaki Michailidou22,77, Roger L Milne51,52, Kenneth Muir72,78, Susan L Neuhausen79, Heli Nevanlinna80, Janet E Olson7, Curtis Olswold7, Jan J C Oosterwijk81, Ana Osorio15,16, Paolo Peterlongo82, Julian Peto45, Paul D P Pharoah22,46, Katri Pylkäs83,84, Paolo Radice85, Muhammad Usman Rashid55,86, Valerie Rhenius46, Anja Rudolph36, Suleeporn Sangrajrang87, Elinor J Sawyer88, Marjanka K Schmidt30, Minouk J Schoemaker89,90, Caroline Seynaeve58, Mitul Shah46, Chen-Yang Shen91,92, Martha Shrubsole93, Xiao-Ou Shu93, Susan Slager7, Melissa C Southey94, Daniel O Stram54, Anthony Swerdlow89,90, Soo H Teo66,67, Ian Tomlinson95, Diana Torres55,96, Thérèse Truong53, Christi J van Asperen8, Lizet E van der Kolk30, Qin Wang22, Robert Winqvist83,84, Anna H Wu54, Jyh-Cherng Yu97, Wei Zheng93, Ying Zheng98, Jennifer Leary99, Logan Walker100, Lenka Foretova73, Florentia Fostira101, Kathleen B M Claes102, Liliana Varesco103, Setareh Moghadasi8, Douglas F Easton22,46, Amanda Spurdle104, Peter Devilee2, Harry Vrieling2, Alvaro N A Monteiro105,106, David E Goldgar107, Aura Carreira3, Maaike P G Vreeswijk2, Fergus J Couch108,7.   

Abstract

Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between 19 BRCA1 and 33 BRCA2 missense substitution variants and breast cancer risk were investigated through a breast cancer case-control study using genotyping data from 38 studies of predominantly European ancestry (41,890 cases and 41,607 controls) and nine studies of Asian ancestry (6,269 cases and 6,624 controls). The BRCA2 c.9104A>C, p.Tyr3035Ser (OR = 2.52; P = 0.04), and BRCA1 c.5096G>A, p.Arg1699Gln (OR = 4.29; P = 0.009) variant were associated with moderately increased risks of breast cancer among Europeans, whereas BRCA2 c.7522G>A, p.Gly2508Ser (OR = 2.68; P = 0.004), and c.8187G>T, p.Lys2729Asn (OR = 1.4; P = 0.004) were associated with moderate and low risks of breast cancer among Asians. Functional characterization of the BRCA2 variants using four quantitative assays showed reduced BRCA2 activity for p.Tyr3035Ser compared with wild-type. Overall, our results show how BRCA2 missense variants that influence protein function can confer clinically relevant, moderately increased risks of breast cancer, with potential implications for risk management guidelines in women with these specific variants. Cancer Res; 77(11); 2789-99. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28283652      PMCID: PMC5508554          DOI: 10.1158/0008-5472.CAN-16-2568

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.

Authors:  Kangjian Wu; Shannon R Hinson; Akihiro Ohashi; Daniel Farrugia; Patricia Wendt; Sean V Tavtigian; Amie Deffenbaugh; David Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

2.  Functional assays for classification of BRCA2 variants of uncertain significance.

Authors:  Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

3.  BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management.

Authors:  Noralane M Lindor; David E Goldgar; Sean V Tavtigian; Sharon E Plon; Fergus J Couch
Journal:  Oncologist       Date:  2013-04-24

4.  A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.

Authors:  Kajal Biswas; Ranabir Das; Blanche P Alter; Sergey G Kuznetsov; Stacey Stauffer; Susan L North; Sandra Burkett; Lawrence C Brody; Stefan Meyer; R Andrew Byrd; Shyam K Sharan
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

Review 5.  A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).

Authors:  Noralane M Lindor; Lucia Guidugli; Xianshu Wang; Maxime P Vallée; Alvaro N A Monteiro; Sean Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

6.  ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.

Authors:  Amanda B Spurdle; Sue Healey; Andrew Devereau; Frans B L Hogervorst; Alvaro N A Monteiro; Katherine L Nathanson; Paolo Radice; Dominique Stoppa-Lyonnet; Sean Tavtigian; Barbara Wappenschmidt; Fergus J Couch; David E Goldgar
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

7.  Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.

Authors:  Megan S Lee; Ruth Green; Sylvia M Marsillac; Nicolas Coquelle; R Scott Williams; Telford Yeung; Desmond Foo; D Duong Hau; Ben Hui; Alvaro N A Monteiro; J N Mark Glover
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

8.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.

Authors:  Haijuan Yang; Philip D Jeffrey; Julie Miller; Elspeth Kinnucan; Yutong Sun; Nicolas H Thoma; Ning Zheng; Phang-Lang Chen; Wen-Hwa Lee; Nikola P Pavletich
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

9.  Purified human BRCA2 stimulates RAD51-mediated recombination.

Authors:  Ryan B Jensen; Aura Carreira; Stephen C Kowalczykowski
Journal:  Nature       Date:  2010-10-07       Impact factor: 49.962

10.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

View more
  24 in total

1.  Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.

Authors:  Hélène Tubeuf; Sandrine M Caputo; Teresa Sullivan; Julie Rondeaux; Sophie Krieger; Virginie Caux-Moncoutier; Julie Hauchard; Gaia Castelain; Alice Fiévet; Laëtitia Meulemans; Françoise Révillion; Mélanie Léoné; Nadia Boutry-Kryza; Capucine Delnatte; Marine Guillaud-Bataille; Linda Cleveland; Susan Reid; Eileen Southon; Omar Soukarieh; Aurélie Drouet; Daniela Di Giacomo; Myriam Vezain; Françoise Bonnet-Dorion; Violaine Bourdon; Hélène Larbre; Danièle Muller; Pascal Pujol; Fátima Vaz; Séverine Audebert-Bellanger; Chrystelle Colas; Laurence Venat-Bouvet; Angela R Solano; Dominique Stoppa-Lyonnet; Claude Houdayer; Thierry Frebourg; Pascaline Gaildrat; Shyam K Sharan; Alexandra Martins
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

2.  Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.

Authors:  Lucia Guidugli; Hermela Shimelis; David L Masica; Vernon S Pankratz; Gary B Lipton; Namit Singh; Chunling Hu; Alvaro N A Monteiro; Noralane M Lindor; David E Goldgar; Rachel Karchin; Edwin S Iversen; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

3.  Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).

Authors:  Hideki Tokunaga; Keita Iida; Atsushi Hozawa; Soichi Ogishima; Yoh Watanabe; Shogo Shigeta; Muneaki Shimada; Yumi Yamaguchi-Kabata; Shu Tadaka; Fumiki Katsuoka; Shin Ito; Kazuki Kumada; Yohei Hamanaka; Nobuo Fuse; Kengo Kinoshita; Masayuki Yamamoto; Nobuo Yaegashi; Jun Yasuda
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

Review 4.  Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation.

Authors:  Alvaro N Monteiro; Peter Bouwman; Arne N Kousholt; Diana M Eccles; Gael A Millot; Jean-Yves Masson; Marjanka K Schmidt; Shyam K Sharan; Ralph Scully; Lisa Wiesmüller; Fergus Couch; Maaike P G Vreeswijk
Journal:  J Med Genet       Date:  2020-03-09       Impact factor: 6.318

5.  Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.

Authors:  Julie L Boyle; Andrew W Hahn; Ashley L Kapron; Wendy Kohlmann; Samantha E Greenberg; Timothy J Parnell; Craig C Teerlink; Benjamin L Maughan; Bing-Jian Feng; Lisa Cannon-Albright; Neeraj Agarwal; Kathleen A Cooney
Journal:  JCO Precis Oncol       Date:  2020-03-04

6.  BRCA2 promotes DNA-RNA hybrid resolution by DDX5 helicase at DNA breaks to facilitate their repair‡.

Authors:  Gaetana Sessa; Belén Gómez-González; Sonia Silva; Carmen Pérez-Calero; Romane Beaurepere; Sonia Barroso; Sylvain Martineau; Charlotte Martin; Åsa Ehlén; Juan S Martínez; Bérangère Lombard; Damarys Loew; Stephan Vagner; Andrés Aguilera; Aura Carreira
Journal:  EMBO J       Date:  2021-02-26       Impact factor: 11.598

7.  Epidemiological and ES cell-based functional evaluation of BRCA2 variants identified in families with breast cancer.

Authors:  Teresa Sullivan; Eswary Thirthagiri; Chan-Eng Chong; Stacey Stauffer; Susan Reid; Eileen Southon; Tiara Hassan; Aravind Ravichandran; Eldarina Wijaya; Joanna Lim; Nur Aishah Mohd Taib; Farhana Fadzli; Cheng Har Yip; Mikael Hartman; Jingmei Li; Rob M van Dam; Susan L North; Ranabir Das; Douglas F Easton; Kajal Biswas; Soo-Hwang Teo; Shyam K Sharan
Journal:  Hum Mutat       Date:  2020-12-31       Impact factor: 4.700

8.  Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.

Authors:  Miriam Deniz; Tatiana Romashova; Sarah Kostezka; Anke Faul; Theresa Gundelach; Maria Moreno-Villanueva; Wolfgang Janni; Thomas W P Friedl; Lisa Wiesmüller
Journal:  Oncotarget       Date:  2017-10-09

9.  Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib.

Authors:  Wajeeha Rizvi; Phu Truong; Quoc Truong
Journal:  Cureus       Date:  2017-06-11

10.  Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Authors:  Andreas Schneeweiss; Michael P Lux; Wolfgang Janni; Andreas D Hartkopf; Naiba Nabieva; Florin-Andrei Taran; Friedrich Overkamp; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Achim Wöckel; Johannes Ettl; Diana Lüftner; Markus Wallwiener; Volkmar Müller; Matthias W Beckmann; Erik Belleville; Diethelm Wallwiener; Sara Y Brucker; Florian Schütz; Peter A Fasching; Tanja N Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-03-21       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.